NTRA – Natera, Inc.
Float Short %
2.58
Margin Of Safety %
-21
Put/Call OI Ratio
0.98
EPS Next Q Diff
0.04
EPS Last/This Y
-0.94
EPS This/Next Y
0.48
Price
212.12
Target Price
258.9
Analyst Recom
1.43
Performance Q
-0.72
Upside
-137.6%
Beta
1.64
Ticker: NTRA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | NTRA | 241.68 | 0.68 | 0.26 | 10212 |
| 2026-01-26 | NTRA | 241.37 | 0.68 | 1.30 | 10273 |
| 2026-01-27 | NTRA | 240.33 | 0.69 | 0.41 | 10357 |
| 2026-01-28 | NTRA | 235.82 | 0.69 | 0.31 | 10455 |
| 2026-01-29 | NTRA | 231.38 | 0.68 | 0.07 | 10545 |
| 2026-01-30 | NTRA | 231.09 | 0.65 | 0.33 | 10864 |
| 2026-02-02 | NTRA | 231 | 0.65 | 0.12 | 10872 |
| 2026-02-03 | NTRA | 227.71 | 0.65 | 0.86 | 10879 |
| 2026-02-05 | NTRA | 197.01 | 0.89 | 0.73 | 12598 |
| 2026-02-09 | NTRA | 211.83 | 1.10 | 0.85 | 15754 |
| 2026-02-10 | NTRA | 211.75 | 1.07 | 0.22 | 16164 |
| 2026-02-11 | NTRA | 212.44 | 1.07 | 0.94 | 16180 |
| 2026-02-12 | NTRA | 208.83 | 1.05 | 2.81 | 16345 |
| 2026-02-13 | NTRA | 206.12 | 1.05 | 2.29 | 16361 |
| 2026-02-17 | NTRA | 211.26 | 1.05 | 0.12 | 16353 |
| 2026-02-18 | NTRA | 215.57 | 1.04 | 0.37 | 16453 |
| 2026-02-19 | NTRA | 216.26 | 1.01 | 3.40 | 16710 |
| 2026-02-20 | NTRA | 212.28 | 0.98 | 0.65 | 16434 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | NTRA | 241.61 | -29.6 | 160.8 | -2.47 |
| 2026-01-26 | NTRA | 241.52 | -29.6 | 160.0 | -2.47 |
| 2026-01-27 | NTRA | 240.33 | -30.2 | 160.6 | -2.47 |
| 2026-01-28 | NTRA | 235.77 | -30.2 | 162.8 | -2.47 |
| 2026-01-29 | NTRA | 231.40 | -30.2 | 162.8 | -2.47 |
| 2026-01-30 | NTRA | 231.14 | -30.2 | 160.2 | -2.47 |
| 2026-02-02 | NTRA | 231.14 | -30.2 | 160.0 | -2.47 |
| 2026-02-03 | NTRA | 227.67 | -30.2 | 162.2 | -2.47 |
| 2026-02-04 | NTRA | 205.66 | -30.2 | 174.4 | -2.47 |
| 2026-02-05 | NTRA | 196.89 | -30.2 | 166.3 | -2.47 |
| 2026-02-06 | NTRA | 203.27 | -30.2 | 155.3 | -2.47 |
| 2026-02-09 | NTRA | 210.48 | -30.2 | 154.5 | -2.47 |
| 2026-02-10 | NTRA | 211.62 | -30.2 | 159.2 | -2.47 |
| 2026-02-11 | NTRA | 212.40 | -30.2 | 159.4 | -2.47 |
| 2026-02-12 | NTRA | 208.01 | -30.2 | 163.1 | -2.47 |
| 2026-02-13 | NTRA | 206.06 | -30.2 | 161.3 | -2.47 |
| 2026-02-17 | NTRA | 211.33 | -30.2 | 156.3 | -2.47 |
| 2026-02-18 | NTRA | 215.55 | -30.2 | 156.9 | -2.47 |
| 2026-02-19 | NTRA | 216.32 | -30.2 | - | -2.47 |
| 2026-02-20 | NTRA | 212.12 | -30.2 | - | -2.47 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | NTRA | -10.07 | -0.35 | 3.61 |
| 2026-01-26 | NTRA | -10.04 | -0.28 | 3.61 |
| 2026-01-27 | NTRA | -10.30 | -0.28 | 3.61 |
| 2026-01-28 | NTRA | -10.32 | -0.28 | 2.63 |
| 2026-01-29 | NTRA | -10.32 | -0.28 | 2.63 |
| 2026-01-30 | NTRA | -10.52 | -0.28 | 2.63 |
| 2026-02-02 | NTRA | -10.29 | 0.06 | 2.63 |
| 2026-02-03 | NTRA | -10.33 | 0.06 | 2.63 |
| 2026-02-04 | NTRA | -10.33 | 0.06 | 2.63 |
| 2026-02-05 | NTRA | -11.59 | 0.06 | 2.63 |
| 2026-02-06 | NTRA | -11.46 | 0.06 | 2.63 |
| 2026-02-09 | NTRA | -11.46 | 0.15 | 2.62 |
| 2026-02-10 | NTRA | -11.61 | 0.15 | 2.62 |
| 2026-02-11 | NTRA | -11.61 | 0.15 | 2.58 |
| 2026-02-12 | NTRA | -11.61 | 0.15 | 2.58 |
| 2026-02-13 | NTRA | -11.53 | 0.15 | 2.58 |
| 2026-02-17 | NTRA | -11.52 | -0.26 | 2.58 |
| 2026-02-18 | NTRA | -11.52 | -0.26 | 2.58 |
| 2026-02-19 | NTRA | -11.52 | -0.26 | 2.58 |
| 2026-02-20 | NTRA | -11.52 | -0.26 | 2.58 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.64
Avg. EPS Est. Current Quarter
-0.58
Avg. EPS Est. Next Quarter
-0.6
Insider Transactions
-11.52
Institutional Transactions
-0.26
Beta
1.64
Average Sales Estimate Current Quarter
576
Average Sales Estimate Next Quarter
613
Fair Value
167.41
Quality Score
44
Growth Score
58
Sentiment Score
97
Actual DrawDown %
17.3
Max Drawdown 5-Year %
-77.7
Target Price
258.9
P/E
Forward P/E
PEG
P/S
13.86
P/B
23.3
P/Free Cash Flow
276.64
EPS
-2.28
Average EPS Est. Cur. Y
-2.47
EPS Next Y. (Est.)
-1.99
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-14.61
Relative Volume
0.96
Return on Equity vs Sector %
-53.7
Return on Equity vs Industry %
-35.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.02
EBIT Estimation
Natera, Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees: 4424
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
stock quote shares NTRA – Natera, Inc. Stock Price stock today
news today NTRA – Natera, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NTRA – Natera, Inc. yahoo finance google finance
stock history NTRA – Natera, Inc. invest stock market
stock prices NTRA premarket after hours
ticker NTRA fair value insiders trading